Want to see TSE:EBM full AI Analyst Report?
Eastwood Bio-Medical Canada (EBM) AI Stock Analysis
Eastwood Bio-Medical Canada
(TSXV:EBM)
The overall score is severely depressed by the company's near-insolvent financial state, with negative equity, persistent losses, and cash burn posing an existential risk. While the stock exhibits strong bullish technical momentum, this is a high-risk speculative trend unsupported by fundamentals. The deeply negative P/E ratio confirms the lack of earnings-based value.
Eastwood Bio-Medical Canada (EBM) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 130.88M
- Dividend Yield
- ―
- Average Volume (3M)
- 9,286
- Price to Earnings (P/E)
- -609.7
- Beta (1Y)
- 0.39
- Revenue Growth
- 36.59%
- EPS Growth
- 43.33%
- Country
- Canada
- Employees
- 3
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Pharmaceuticals
Eastwood Bio-Medical Canada Business Overview & Revenue Model
Company Description
Eastwood Bio-Medical Canada Inc., established in Richmond, Canada, in 2010, is a company focused on the worldwide marketing and distribution of natural health products. Operating under the Eleotin brand, their offerings are available across Canada, t...
Eastwood Bio-Medical Canada Financial Statement Overview
Summary
Financial health is critically poor. The company is technically insolvent with negative equity of -$1.78M, deeply negative profit margins (-28.5% net), and negative operating and free cash flow. A recent revenue spike to $812K and a 66.3% gross margin offer a faint glimmer of product viability, but this is overwhelmed by the unsustainable cost structure and cash burn.
Income Statement
18Very NegativeBalance Sheet
5Very NegativeCash Flow
10Very Negative| Breakdown | TTM | Jan 2026 | Jan 2025 | Oct 2023 | Oct 2022 | Jan 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 812.12K | 782.08K | 702.08K | 867.94K | 1.30M | 981.05K |
| Gross Profit | 538.18K | 506.03K | 454.39K | 440.51K | 902.74K | 458.37K |
| EBITDA | -238.60K | -309.73K | -342.05K | -410.58K | -32.33K | -495.50K |
| Net Income | -231.56K | -332.77K | -455.87K | -546.60K | -160.58K | -611.34K |
Balance Sheet | ||||||
| Total Assets | 256.96K | 218.77K | 274.29K | 489.14K | 584.53K | 691.12K |
| Cash, Cash Equivalents and Short-Term Investments | 3,528 | 17.70K | 0 | 18.45K | 39.84K | 20.87K |
| Total Debt | 63.65K | 78.01K | 79.61K | 23.08K | 62.25K | 31.35K |
| Total Liabilities | 2.04M | 1.85M | 1.57M | 1.33M | 878.73K | 835.44K |
| Stockholders Equity | -1.78M | -1.63M | -1.30M | -840.80K | -294.20K | -144.32K |
Cash Flow | ||||||
| Free Cash Flow | -9,420 | 19.30K | -15.22K | -16.89K | -7,299 | -121.79K |
| Operating Cash Flow | -9,428 | 19.30K | -15.22K | -16.89K | -4,294 | -116.21K |
| Investing Cash Flow | 0 | 0 | 0 | 0 | -3,005 | -5,574 |
| Financing Cash Flow | -7,688 | -211 | -4,619 | -4,503 | 26.27K | 20.00K |
Eastwood Bio-Medical Canada Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:EBM, the sentiment is Neutral. The current price of 1.80 is below the 20-day moving average (MA) of 1.88, below the 50-day MA of 1.87, and above the 200-day MA of 1.10, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 51.48 is Neutral, neither overbought nor oversold. The STOCH value of 83.06 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:EBM.
Eastwood Bio-Medical Canada Peers Comparison
Overall Rating
- TSE:EBM46Neutral
TSE:ATLE42Neutral
TSE:ARCH41Neutral
TSE:SONA40Underperform
TSE:ADK38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TSE:EBM | 46Neutral | CAD 130.88M | -609.68 | 13.66% | ― | 36.59% | 43.33% |
| TSE:ATLE | 42Neutral | CAD 41.96M | -0.76 | -2099.75% | ― | -100.00% | 94.43% |
| TSE:ARCH | 41Neutral | CAD 56.38M | -18.59 | 74.79% | ― | ― | -15.53% |
| TSE:SONA | 40Underperform | CAD 34.38M | -13.32 | 448.05% | ― | ― | 24.65% |
| TSE:ADK | 38Underperform | CAD 40.34M | -8.47 | 9999.00% | ― | -36.92% | 13.03% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:EBM | Eastwood Bio-Medical Canada | 1.89 | 1.14 | 152.00% | |
| TSE:ARCH | Arch Biopartners | 0.79 | -0.24 | -23.30% | |
| TSE:ADK | Diagnos Inc | 0.35 | 0.03 | 9.37% | |
| TSE:ATLE | Willow Biosciences | 0.09 | -0.09 | -50.00% | |
| TSE:ZYUS | Zyus Life Sciences Corporation | 0.32 | -0.38 | -54.29% | |
| TSE:SONA | Sona Nanotech, Inc | 0.28 | -0.32 | -52.50% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 01, 2026